Cancer Drugs Fund

Articles

The new Cancer Drugs Fund: sticking plaster 2.0 or a model f...

A new, value-based Cancer Drugs Fund is set to be launched in England soon, but pharma companies fear it will be a step backwards for access to new cancer medicines.

Articles

End-of-life treatments: what will NICE accept?

As consultation on the 'new' Cancer Drugs Fund closes this week, Leela Barham reviews the impact of England's guidance on end-of-life treatments and the implications of these broader changes.

Cancer

AZ withdraws cancer drug Lynparza from CDF evaluation

On the day that England's Cancer Drugs Fund (CDF) reduced the number of indications it will fund to 59 from 84, AstraZeneca (AZ) announced that it had withdrawn its ovarian cancer drug Lynp

News

Roche challenges NICE on Kadcyla and ignoring pricing deal

Row over breast cancer drug Kadcyla continues

The new Cancer Drugs Fund: sticking plaster 2.0 or a model f...

End-of-life treatments: what will NICE accept?

AZ withdraws cancer drug Lynparza from CDF evaluation

Roche challenges NICE on Kadcyla and ignoring pricing deal

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

Cancer Drugs Fund

Editor's Picks